Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10O2 |
Molecular Weight | 222.2387 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1C(C(=O)C2=C1C=CC=C2)C3=CC=CC=C3
InChI
InChIKey=NFBAXHOPROOJAW-UHFFFAOYSA-N
InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1930 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3781349 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | HEDULIN Approved UsePhenindione is a synthetic anticoagulant which acts by interfering with the formation of factors II, VII, IX and X. It produces its effect in 36-48 hours after the initial dose; the effect wanes over a period of 48-72 hours after phenindione is stopped. |
|||
Primary | HEDULIN Approved UsePhenindione is a synthetic anticoagulant which acts by interfering with the formation of factors II, VII, IX and X. It produces its effect in 36-48 hours after the initial dose; the effect wanes over a period of 48-72 hours after phenindione is stopped. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
175 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/535602/ |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENINDIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
393 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/535602/ |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENINDIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/535602/ |
30 mg/kg single, intravenous dose: 30 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENINDIONE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5 h |
125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENINDIONE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12% |
125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENINDIONE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
75 mg 1 times / day multiple, oral (mean) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, 53 years n = 1 Health Status: unhealthy Age Group: 53 years Sex: M Population Size: 1 Sources: |
Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice (1 patient) Sources: |
100 mg 1 times / day multiple, oral (mean) Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, 63 years n = 1 Health Status: unhealthy Age Group: 63 years Sex: M Population Size: 1 Sources: |
Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Jaundice | 1 patient Disc. AE |
75 mg 1 times / day multiple, oral (mean) Studied dose Dose: 75 mg, 1 times / day Route: oral Route: multiple Dose: 75 mg, 1 times / day Sources: |
unhealthy, 53 years n = 1 Health Status: unhealthy Age Group: 53 years Sex: M Population Size: 1 Sources: |
Jaundice | 1 patient Disc. AE |
100 mg 1 times / day multiple, oral (mean) Studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy, 63 years n = 1 Health Status: unhealthy Age Group: 63 years Sex: M Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27925230/ Page: 2.0 |
slight or no effect | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27925230/ Page: 2.0 |
slight or no effect |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27925230/ Page: 11.0 |
likely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27925230/ Page: 11.0 |
likely |
PubMed
Title | Date | PubMed |
---|---|---|
Sustained release of propranolol hydrochloride based on ion-exchange resin entrapped within polystyrene microcapsules. | 2006 Dec |
|
Acute immuno-allergic interstitial nephritis caused by fluindione. | 2006 Dec |
|
Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. | 2006 Jun |
|
Preparation and in vitro evaluation of polystyrene-coated diltiazem-resin complex by oil-in-water emulsion solvent evaporation method. | 2006 May 26 |
|
A green method for the electroorganic synthesis of new 1,3-Indandione derivatives. | 2006 Oct |
|
Can cryoglobulins interfere with the measurement of IgM antiphosphatidylethanolamine antibodies by ELISA? | 2007 |
|
Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). | 2007 Apr |
|
[Advice for patients taking oral anticoagulants (coumadin or Previscan)]. | 2007 Apr 15 |
|
Identification of selective ion-exchange resin for fluoride sorption. | 2007 Apr 15 |
|
Acute thrombosis of a prosthetic mitral valve: a lesson in anticoagulation. | 2007 Aug |
|
[Liver toxicity associated with oral anticoagulant treatment: report of two cases]. | 2007 Jun-Jul |
|
Iron and manganese contamination: sources, adverse effects and control methods. | 2007 Oct |
|
Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. | 2007 Oct |
|
[Modification of an antitumor action of photodynamic therapy with anticoagulant drug fenylin]. | 2007 Oct-Dec |
|
Taste mask, design and evaluation of an oral formulation using ion exchange resin as drug carrier. | 2008 |
|
[Fluindione-induced acute generalised exanthematous pustulosis confirmed by patch testing]. | 2008 Apr |
|
Colchicine: serious interactions. | 2008 Aug |
|
[Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control]. | 2008 Dec |
|
Analysis of indandione anticoagulant rodenticides in animal liver by eluent generator reagent free ion chromatography coupled with electrospray mass spectrometry. | 2008 Dec 5 |
|
Development and evaluation of oral controlled release chlorpheniramine-ion exchange resinate suspension. | 2008 Jul-Aug |
|
Severe hemorrhagic syndrome due to similarity of drug names. | 2008 Mar |
|
Chemical substructures that enrich for biological activity. | 2008 Nov 1 |
|
Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients. | 2008 Nov-Dec |
|
Self-control of long-term oral anticoagulation using a point-of-care device. | 2008 Nov-Dec |
|
[Hepatic and renal toxicity to fluindione (Previscan)]. | 2008 Oct |
|
[Acute interstitial nephritis of fluindione: about three cases]. | 2008 Oct |
|
Evaluation of the palatability of three nonsteroidal antiinflammatory top-dress formulations in horses. | 2008 Summer |
|
Potentiometric determination of ionisation constants for diphacinone and chlorophacinone in a dioxane-water cosolvent system. | 2009 Aug 15 |
|
Combinatorial mutasynthesis of scrambled beauvericins, cyclooligomer depsipeptide cell migration inhibitors from Beauveria bassiana. | 2009 Jan 26 |
|
Formulation and optimization of sustained release tablets of venlafaxine resinates using response surface methodology. | 2009 Jul |
|
[Acute immuno-allergic interstitial nephritis after treatment with fluindione. Seven cases]. | 2009 Jul |
|
A new VKORC1 mutation leading to an isolated resistance to fluindione. | 2009 Jun |
|
[Liver infarcts with early HELLP syndrome and probable catastrophic antiphospholipid syndrome]. | 2009 Mar |
|
[Necrotizing folliculitis in Behçet's disease]. | 2009 Mar |
|
[Multidrug intoxication]. | 2009 Mar-Apr |
|
Budd-Chiari syndrome as a vascular complication of amebic liver abscess. | 2009 Nov |
|
[Inefficacy of vitamin K antagonists in an human immunodeficiency virus seropositive patient taking nevirapine]. | 2009 Nov |
|
Conservative treatment of spontaneous and isolated dissection of mesenteric arteries. | 2009 Nov-Dec |
|
Use the INN to avoid confusion between drugs. | 2009 Oct |
|
[Severe overdose in vitamin K antagonist secondary to grapefruit juice absorption]. | 2009 Oct |
|
Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism. | 2009 Oct |
|
Effects of ion exchange resins in different mobile ion forms on semi-aerobic landfill leachate treatment. | 2010 |
|
[Simultaneous determination of trace diphacinone and chlorophacinone in biological samples by high performance liquid chromatography coupled with ion trap mass spectrometry]. | 2010 Feb |
|
[Thrombosis of the inferior vena cava revealing primary antiphospholipid syndrome: a case report]. | 2010 Feb |
|
Formulation and evaluation of rizatriptan benzoate mouth disintegrating tablets. | 2010 Jan |
|
A novel prodrug strategy for beta-dicarbonyl carbon acids: syntheses and evaluation of the physicochemical characteristics of C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrug derivatives. | 2010 Jun |
|
Validation of a new liquid chromatography- tandem mass spectrometry ion-trap technique for the simultaneous determination of thirteen anticoagulant rodenticides, drugs, or natural products. | 2010 Mar |
|
[Glycopeptide-induced cutaneous adverse reaction]. | 2010 May |
|
Acute toxicity of diphacinone in Northern bobwhite: effects on survival and blood clotting. | 2010 Sep |
|
Taste masking of Etoricoxib by using ion-exchange resin. | 2010 Sep-Oct |
Patents
Sample Use Guides
Initial: orally 200 mg in 2 equal doses on day 1, then 100 mg on day 2. Maintenance: 50-150 mg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3781349
Experiments for determination of inhibition of vitamin-K-dependent carboxylation was determined using preparation of rat liver microsomes. Experimental reaction mixtures contained both vitamin K and a vitamin K antagonist. The control reaction mixture contained 3.00 ml of microsomal suspension, 0.81 ml of buffer II. 1.20 ml of an ATP-generating system, 0.60 ml of NADH (final concentration 2 mM), 0.30 ml of dithiothreitol (final concentration 7 m.V/) in buffer II. 0.060 ml of NaH[14C]O3 (1.0 uCi/uL added 0.5 min prior to reaction initiation) and at the time of reaction initiation 0.030 ml of vitamin K (final concentration 20 ug/ml) diluted in 0.85% sodium chloride solution. Reaction mixtures were equilibrated at 27 °C in a reciprocating shaker water bath at 100 excursions per minute. Serial samples (0.45 ml each) were collected from each control and blank reaction tube at 2,4, 6, 8, 10, 12, 14, 16, 30, 60, 90 and 120 min, and from each experimental reaction tube at 2,4, 6, 8, 10, 12, 14 and 16 min. Each sample was transferred to a tube containing I ml of ice-cold 10% TCA. Amount of product formed was determined using liquid scintillation spectrometer with the external standard method of quench correction. Phenindione inhibits Vitamin K-dependent carboxylation with IC50 of 19 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
B01AA02
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
||
|
WHO-VATC |
QB01AA02
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8130
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
C66371
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
SUB09765MIG
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
PHENINDIONE
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
41693
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
D010630
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
201-454-4
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
DB00498
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
23
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
100000082255
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
83-12-5
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
CHEMBL711
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
5M7Y6274ZE
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
4760
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
3155
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
2130
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
DTXSID5023453
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
8066
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | |||
|
m8618
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY | Merck Index | ||
|
6838
Created by
admin on Fri Dec 15 15:06:45 UTC 2023 , Edited by admin on Fri Dec 15 15:06:45 UTC 2023
|
PRIMARY |
ACTIVE MOIETY